$19.24
0.05% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US8523123052
Symbol
STAA

STAAR Surgical Company Stock price

$19.24
+2.71 16.39% 1M
-7.08 26.90% 6M
-5.05 20.79% YTD
-23.56 55.05% 1Y
-40.40 67.74% 3Y
-19.72 50.62% 5Y
+10.10 110.50% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.01 0.05%
ISIN
US8523123052
Symbol
STAA
Sector

Key metrics

Market capitalization $952.88m
Enterprise Value $766.80m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.75
P/S ratio (TTM) P/S ratio 3.41
P/B ratio (TTM) P/B ratio 2.72
Revenue growth (TTM) Revenue growth -14.44%
Revenue (TTM) Revenue $279.13m
EBIT (operating result TTM) EBIT $-67.73m
Free Cash Flow (TTM) Free Cash Flow $-31.35m
Cash position $222.76m
EPS (TTM) EPS $-1.44
P/E forward negative
P/S forward 3.70
EV/Sales forward 2.98
Short interest 27.98%
Show more

Is STAAR Surgical Company a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

STAAR Surgical Company Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a STAAR Surgical Company forecast:

3x Buy
21%
10x Hold
71%
1x Sell
7%

Analyst Opinions

14 Analysts have issued a STAAR Surgical Company forecast:

Buy
21%
Hold
71%
Sell
7%

Financial data from STAAR Surgical Company

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
279 279
14% 14%
100%
- Direct Costs 74 74
6% 6%
27%
205 205
20% 20%
73%
- Selling and Administrative Expenses 211 211
17% 17%
76%
- Research and Development Expense 54 54
14% 14%
19%
-60 -60
310% 310%
-21%
- Depreciation and Amortization 7.99 7.99
46% 46%
3%
EBIT (Operating Income) EBIT -68 -68
394% 394%
-24%
Net Profit -71 -71
565% 565%
-25%

In millions USD.

Don't miss a Thing! We will send you all news about STAAR Surgical Company directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

STAAR Surgical Company Stock News

Neutral
Business Wire
5 days ago
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $30 million of its outstanding common stock. “Our decision to initiate...
Negative
Seeking Alpha
7 days ago
Sales in China were severely impacted due to inventory de-stocking, but the outlook for the region for H2 2025 looks promising. Global sales ex-China were weak, with management choosing to withdraw the earlier guidance for revenue growth of 9–15%. I expect revenue and earnings of $320 million and $23 million, respectively, for next year, which puts the current valuation at 43.5 times earnings.
Neutral
Seeking Alpha
13 days ago
STAAR Surgical Company. (NASDAQ:STAA ) Q1 2025 Earnings Conference Call May 7, 2025 5:15 PM ET Company Participants Brian Moore - VP, Investor Relations and Corporate Development Stephen Farrell - Chair of the Board, President and CEO Warren Faust - President and COO Deborah Andrews - Interim CFO Conference Call Participants Tom Stephan - Stifel Anthony Petrone - Mizuho Ryan Zimmerman - BTIG Pa...
More STAAR Surgical Company News

Company Profile

STAAR Surgical Co. engages in the development, manufacture, production, marketing, and sale of implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It specializes in refractive and cataract solutions. Its products include intraocular lens and implantable collamer lens. The company was founded in 1982 and is headquartered in Lake Forest, CA.

Head office United States
CEO Stephen Farrell
Employees 1,211
Founded 1982
Website www.staar.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today